The Physics of Intraoperative Dose Planning for Focal Brachytherapy

Ren-Dih Sheu, PhD, DABR, Associate Professor of Radiation Oncology at the Icahn School of Medicine at Mount Sinai in New York, New York, presents an overview of intraoperative dose planning for focal brachytherapy in prostate cancer treatment. In this 16-minute presentation, Dr. Sheu covers the steps for determining the initial dose and other patient-specific factors affecting the implementation of focal brachytherapy, emphasizes the importance of high Biologically Effective Doses (BEDs) in preventing recurrence, and provides the audience with the equations for determining appropriate BED in Brachytherapy and EBRT patients.

[spitfirekid]

I appreciate the content on this channel. Thank you for posting these informative videos.

I had focal Brachytherapy in 2020. My lowest PSA rating was 2.21. My oncologist had no follow up plan for subsequent MRIs, PET, PSMA, scans, or biopsies. He simply monitored my PSA, even when my PSA reached 3.75. I found a new doctor, had a new MRI and a PETPSMA scan and they found extensive cancer recurrence with possible lymph node involvement. My best chance for remission requires salvage prostatectomy which is high risk for incontinence and severe ED; all thanks to the lack of a good follow up plan.

I suggest that anyone reading this who is considering any kind of focal therapy for prostate cancer ask their doctor what their plan is to monitor their condition, so that a recurrence is caught sooner rather than later. Don’t let this happen to you